Validation Study on the Removal of EpCAM-positive Tumour Cells From Blood Collected During Tumour Surgery Using Catumaxomab/Catuvab Device

Inclusion Criteria: * Intraoperative blood salvage (IBS)-eligible according to the Investigator * Patients with a prostate tumor, gallbladder carcinoma, bladder carcinoma, endometrial carcinoma, gastric carcinoma, ovarian carcinoma, pancreatic carcinoma, colon / rectal carcinoma, non-small cell lung cancer, or peritoneal carcinomatosis, i.e., cancer types with a high likelihood of being EpCAM-positive (\>92%) OR kidney carcinoma or liver carcinoma. * For patients with cancer types with a high likelihood of being EpCAM-positive (\>92%): if a tumor tissue sample is available and has been EpCAM tested or EpCAM-testing can be done within 5 days of signing the informed consent form (ICF): results of EpCAM typing should be positive. * For patients with kidney carcinoma or liver carcinoma: a tumor tissue sample must be available and have tested EpCAM-positive prior to surgery. * Scheduled for surgery to remove tumor. * The Investigator expects that at least 400 mL full blood can be collected during the tumor surgery. * An American Society of Anesthesiologists (ASA) Classification of ≤3. Exclusion Criteria: * Adjuvant therapy and intra-operative chemotherapy (hyperthermic intraperitoneal hemotherapy, HIPEC) started before blood collection for IBS is completed. * Lymphocytopenia (count \<1.0 x 109 /L lymphocytes). * Cancer different from indicated types, especially typically EpCAM-negative tumor types. * Sepsis occurring during surgery. * Cirrhosis of the liver with a Child-Pugh sc…